Beijing Medical and Health Industry Investment Fund
北京市医药健康产业投资基金
The Beijing Medical and Health Industry Investment Fund (北京市医药健康产业投资基金) is one of eight sector-specific government guidance funds under Beijing State-owned Assets Management (北京国管), with a total initial scale of 100 billion RMB across all eight funds . It is managed by C-Bridge Capital (康桥资本), a healthcare-focused investment firm .
The fund operates as a government-backed capital vehicle targeting Beijing's healthcare and biotech industries. It has been particularly active in gene editing and cell therapy, leading Qihe Biotech's (齐禾生科) over 200 million RMB Series A in late 2024 and co-leading Jitai Technology's (剂泰科技) 400 million RMB Series D in late 2025 . It also participated in Huaxin Biotech's (华龛生物) Series B+ round in 2025 alongside multiple other state-backed funds including the Beijing New Materials Industry Investment Fund .
The fund represents a broader pattern of Beijing municipal government deploying sector-differentiated industrial capital—each fund assigned to a specialized GP with minimal overlap in mandate .
AI-generated — may contain errors, please verify.
Coverage
From Two Rounds in Six Months to a $400M Series D: 10 Companies Announce New Funding | FreeS Family Funding News Vol.24
Looking forward to working alongside more outstanding founders.
3D Cell Manufacturing Platform Huaxin Biotech Closes Series B+ Round to Accelerate Cell Therapy Commercialization for Global Clients
Ushering in the 2.0 era of cell-based industrialization.
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Qihe Biotech Closes Over RMB 200 Million Series A to Accelerate Gene Editing R&D and Commercialization
Develop novel gene-editing technologies to create exceptional biological traits and products.
